1-8 of 8
Maja J. A. de Jonge
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I and Pharmacokinetic Study of DE-310 in Patients with Advanced Solid Tumors

Otto Soepenberg, Maja J. A. de Jonge, Alex Sparreboom, Peter de Bruin, Ferry A. L. M. Eskens, Gerda de Heus, Jantien Wanders, Peter Cheverton, Murray P. Ducharme, Jaap Verweij
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (2): 703–711.
https://doi.org/10.1158/1078-0432.703.11.2
Published: 08 February 2005
View article titled, Phase I and Pharmacokinetic Study of DE-310 in Patients with Advanced Solid Tumors
Open the PDF for Phase I and Pharmacokinetic Study of DE-310 in Patients with Advanced Solid Tumors in another window
Journal Articles

Phase I Pharmacological and Bioavailability Study of Oral Diflomotecan (BN80915), a Novel E-Ring-modified Camptothecin Analogue in Adults with Solid Tumors

Hans Gelderblom, Ramon Salazar, Jaap Verweij, George Pentheroudakis, Maja J. A. de Jonge, Martin Devlin, Christel van Hooije, Francis Seguy, Rosendo Obach, Joan Pruñonosa, Paola Principe, Chris Twelves
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (11): 4101–4107.
Published: 30 September 2003
View article titled, Phase I Pharmacological and Bioavailability Study of Oral Diflomotecan (BN80915), a Novel E-Ring-modified Camptothecin Analogue in Adults with Solid Tumors
Open the PDF for Phase I Pharmacological and Bioavailability Study of Oral Diflomotecan (BN80915), a Novel E-Ring-modified Camptothecin Analogue in Adults with Solid Tumors in another window
Journal Articles

Phase I and Pharmacokinetic Study of Brostallicin (PNU-166196), a New DNA Minor-Groove Binder, Administered Intravenously Every 3 Weeks to Adult Patients with Metastatic Cancer

Albert J. ten Tije, Jaap Verweij, Alex Sparreboom, Ate van der Gaast, Camilla Fowst, Francesco Fiorentini, Jennifer Tursi, Alessandro Antonellini, Marijke Mantel, Carla M. Hartman, Gerrit Stoter, Andre S. T. Planting, Maja J. A. de Jonge
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (8): 2957–2964.
Published: 11 August 2003
View article titled, Phase I and Pharmacokinetic Study of Brostallicin (PNU-166196), a New DNA Minor-Groove Binder, Administered Intravenously Every 3 Weeks to Adult Patients with Metastatic Cancer
Open the PDF for Phase I and Pharmacokinetic Study of Brostallicin (PNU-166196), a New DNA Minor-Groove Binder, Administered Intravenously Every 3 Weeks to Adult Patients with Metastatic Cancer in another window
Journal Articles

Modulation of Irinotecan-induced Diarrhea by Cotreatment with Neomycin in Cancer Patients

Diederik F. S. Kehrer, Alex Sparreboom, Jaap Verweij, Peter de Bruijn, Corine A. Nierop, Jacqueline van de Schraaf, Elisabeth J. Ruijgrok, Maja J. A. de Jonge
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (5): 1136–1141.
Published: 01 May 2001
View article titled, Modulation of Irinotecan-induced Diarrhea by Cotreatment with Neomycin in Cancer Patients
Open the PDF for Modulation of Irinotecan-induced Diarrhea by Cotreatment with Neomycin in Cancer Patients in another window
Journal Articles

Factors Involved in Prolongation of the Terminal Disposition Phase of SN-38: Clinical and Experimental Studies

Diederik F. S. Kehrer, Wataru Yamamoto, Jaap Verweij, Maja J. A. de Jonge, Peter de Bruijn, Alex Sparreboom
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (9): 3451–3458.
Published: 01 September 2000
View article titled, Factors Involved in Prolongation of the Terminal Disposition Phase of SN-38: Clinical and Experimental Studies
Open the PDF for Factors Involved in Prolongation of the Terminal Disposition Phase of SN-38: Clinical and Experimental Studies in another window
Journal Articles

Inter- and Intrapatient Variability in Oral Topotecan Pharmacokinetics: Implications for Body-Surface Area Dosage Regimens

Walter J. Loos, Hans Gelderblom, Alex Sparreboom, Jaap Verweij, Maja J. A. de Jonge
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (7): 2685–2689.
Published: 01 July 2000
View article titled, Inter- and Intrapatient Variability in Oral Topotecan Pharmacokinetics: Implications for Body-Surface Area Dosage Regimens
Open the PDF for Inter- and Intrapatient Variability in Oral Topotecan Pharmacokinetics: Implications for Body-Surface Area Dosage Regimens in another window
Journal Articles

Topotecan Lacks Third Space Sequestration

Hans Gelderblom, Walter J. Loos, Jaap Verweij, Maja J. A. de Jonge, Alex Sparreboom
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (4): 1288–1292.
Published: 01 April 2000
View article titled, Topotecan Lacks Third Space Sequestration
Open the PDF for Topotecan Lacks Third Space Sequestration in another window
Journal Articles

Drug-Administration Sequence Does Not Change Pharmacodynamics and Kinetics of Irinotecan and Cisplatin

Maja J. A. de Jonge, Jaap Verweij, André S. T. Planting, Maria E. L. van der Burg, Gerrit Stoter, Maureen M. de Boer-Dennert, Peter de Bruijn, Eric Brouwer, Laurent Vernillet, Alex Sparreboom
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (8): 2012–2017.
Published: 01 August 1999
View article titled, Drug-Administration Sequence Does Not Change Pharmacodynamics and Kinetics of Irinotecan and Cisplatin
Open the PDF for Drug-Administration Sequence Does Not Change Pharmacodynamics and Kinetics of Irinotecan and Cisplatin in another window